Evercore ISI Group Maintains Outperform on BridgeBio Pharma, Lowers Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group maintains an Outperform rating on BridgeBio Pharma (NASDAQ:BBIO) but lowers the price target from $50 to $45.
August 07, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Evercore ISI Group maintains an Outperform rating on BridgeBio Pharma but lowers the price target from $50 to $45.
The Outperform rating suggests continued confidence in BridgeBio Pharma's performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100